ACRV vs. LFCR, TRVI, GALT, RIGL, OMER, GBIO, OVID, ALIM, ATOS, and OGI
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Lifecore Biomedical (LFCR), Trevi Therapeutics (TRVI), Galectin Therapeutics (GALT), Rigel Pharmaceuticals (RIGL), Omeros (OMER), Generation Bio (GBIO), Ovid Therapeutics (OVID), Alimera Sciences (ALIM), Atossa Therapeutics (ATOS), and Organigram (OGI). These companies are all part of the "pharmaceutical preparations" industry.
Lifecore Biomedical (NASDAQ:LFCR) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.
Lifecore Biomedical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Acrivon Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Acrivon Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Acrivon Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.32 beat Acrivon Therapeutics' score of 0.95 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.
Acrivon Therapeutics received 22 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 95.83% of users gave Acrivon Therapeutics an outperform vote while only 12.50% of users gave Lifecore Biomedical an outperform vote.
83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 14.6% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 7.3% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Acrivon Therapeutics' return on equity of 0.00% beat Lifecore Biomedical's return on equity.
Lifecore Biomedical currently has a consensus target price of $9.50, suggesting a potential upside of 51.27%. Acrivon Therapeutics has a consensus target price of $22.63, suggesting a potential upside of 157.98%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Lifecore Biomedical.
Summary
Acrivon Therapeutics beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
